1. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization;2014.
2. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 2nd ed. Cheongju: Korea Centers for Disease Control and Prevention;2014.
3. Serbina NV, Flynn JL. Early emergence of CD8
+ T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice. Infect Immun. 1999; 67:3980–3988. PMID:
10417164.
Article
4. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001; 19:93–129. PMID:
11244032.
Article
5. Thia KT, Loftus EV Jr. , Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008; 103:3167–3182. PMID:
19086963.
6. Lee KM, Jeen YT, Cho JY, et al. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol. 2013; 28:1829–1833. PMID:
23829336.
Article
7. Kim YJ, Kim JW, Lee CK, et al. Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience. Korean J Gastroenterol. 2013; 61:270–278. PMID:
23756669.
Article
8. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am. 2004; 30:237–255. PMID:
15172038.
9. Imperato AK, Bingham CO 3rd, Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol. 2004; 22(5 Suppl 35):S108–S114. PMID:
15552523.
10. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010; 36:1185–1206. PMID:
20530046.
Article
11. Chung KB, Lee EY, Im JP, Han SK, Yim JJ. Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor. Korean J Intern Med. 2013; 28:174–179. PMID:
23525649.
Article
12. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007; 34:706–711. PMID:
17309133.
13. Suh YS, Kwok SK, Ju JH, Park KS, Park SH, Yoon CH. Safe readministration of tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy. J Korean Med Sci. 2014; 29:38–42. PMID:
24431903.
Article
14. Yoo IK, Choung RS, Hyun JJ, et al. Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-alpha therapy. Yonsei Med J. 2014; 55:442–448. PMID:
24532516.
Article
15. Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scand J Gastroenterol. 2015; 50:312–320. PMID:
25581784.
Article
16. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010; 69:522–528. PMID:
19854715.
Article
17. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009; 60:1884–1894. PMID:
19565495.
Article
18. Kwon YS, Koh WJ. Diagnosis of pulmonary tuberculosis and nontuberculous mycobacterial lung disease in Korea. Tuberc Respir Dis (Seoul). 2014; 77:1–5. PMID:
25114696.
Article
19. Shim TS. Diagnosis and treatment of latent tuberculosis infection in patients with inflammatory bowel diseases due to initiation of anti-tumor necrosis factor therapy. Intest Res. 2014; 12:12–19. PMID:
25349559.
Article
20. Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014; 27:3–20. PMID:
24396134.
Article
21. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med. 1971; 285:1506–1509. PMID:
5127141.
Article
22. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000; 161:1376–1395. PMID:
10764337.
23. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345:1098–1104. PMID:
11596589.
Article
24. Kim ES, Song GA, Cho KB, et al. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J Gastroenterol. 2015; 21:3308–3316. PMID:
25805938.
Article
25. Ko WY, Shon HJ, Lee HK, et al. Annual Report on the Notified Tuberculosis in Korea 2014. Korea Centers for Disease Control and Prevention;2015.
26. Abreu C, Magro F, Santos-Antunes J, et al. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis. 2013; 7:e486–e492. PMID:
23583099.
Article
27. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004; 50:372–379. PMID:
14872478.
Article